Relay Therapeutics, Inc. · NASDAQ:RLAY

Relay Therapeutics — J.P. Morgan Healthcare Conference 2024

32 slides from Relay Therapeutics's conference presentation, Jan 8, 2024

  1. Slide 1: J.P. Morgan Conference Presentation January 2024

    J.P. Morgan Conference Presentation January 2024 Exhibit 99.1

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the progress and timing of the clinical development of the programs across

  3. Slide 3: Relay Tx – Productive and Evolving Platform

    Relay Tx – Productive and Evolving Platform PEOPLE Chemical biology insights Deep structural understanding Physics-based simulations AI / ML EXPERIMENTATION COMPUTATION PEOPLE ~$811M Cash, cash equivalents and investments as of the end of 3Q 2023 Pipeline 7+ pre-clinical programs TAs Oncology and Ge

  4. Slide 4: Dynamo Platform – Evolution to Highly Integrated Tools & Team

    2016 Exp. Comp. Relay Tx’s Dynamo™ Platform – Evolution to Highly Integrated Tools & Team 2020 Exp. Comp. 2024 Dynamo Platform COMPUTATION PEOPLE EXPERIMENTATION Degrader Design ML-DEL Automated Chem Design

  5. Slide 5: Relay Tx – Productive Platform Against Intractable Challenges

    Relay Tx – Productive Platform Against Intractable Challenges FGFR2 FGFR1 FGFR2 Lirafugratinib (RLY-4008): Isoform Selective 2020 PI3Kα RLY-2608: Mutant Selective 2021 Migoprotafib (GDC-1971): Rapid proof of platform SHP2 2019

  6. Slide 6: Relay Tx – Broad Precision Medicine Pipeline

    Relay Tx – Broad Precision Medicine Pipeline Target Program Annual US Patient # PI3Kα franchise RLY-2608 PI3KαPAN Monotherapy ~10-71K breast cancer ~76-243K all solid tumors Endocrine Tx (ET) doublet CDK4/6i + ET triplet RLY-5836 (PI3KαPAN) Dose Escalation PI3KαH1047R ~4-27K breast cancer ~15-50K al

  7. Slide 7: Relay Tx – Strategic Focus

    Relay Tx – Strategic Focus Early-Stage Research Programs 7+ pre-clinical programs in Oncology and Genetic Disease New program(s) to be disclosed in 2024 RLY-2608 Pan-mutant selective PI3Kα inhibitor RLY-2608 selected over RLY-5836 Ribociclib triplet initiated Lirafugratinib (RLY-4008) Selective FGFR

  8. Slide 8: Relay Tx – Broad Precision Medicine Pipeline

    Relay Tx – Broad Precision Medicine Pipeline Target Program PI3Kα franchise RLY-2608 PI3KαPAN Monotherapy Endocrine Tx (ET) doublet CDK4/6i + ET triplet RLY-5836 (PI3KαPAN) Dose Escalation PI3KαH1047R CDK2 RLY-2139 ERα RLY-1013 (Degrader) FGFR2 Lirafugratinib (RLY-4008) Solid Tumor 2 programs Geneti

  9. Slide 9: Breast Cancer – Evolving Landscape With Very Large Market Opportunity

    Breast Cancer – Evolving Landscape With Very Large Market Opportunity $27B Market Size of (Neo)adjuvant and 1L Metastatic HR+/HER2- Breast Cancer (Neo)adjuvant & 1L Metastatic HR+/HER2- Breast Cancer Later Line BC Current Tx Evolving SoC * Inavolisib is an investigational therapy in Ph3 studies Sour

  10. Slide 10: PI3Kα Represents a Major Market Opportunity

    PI3Kα Represents a Major Market Opportunity 14% of all solid tumors with PI3Kα mutation All Solid Tumors 35% of Breast Cancer patients have PI3Kα mutation Breast Cancer ~150k US HR+/HER2- Breast Cancer Patients1 with PI3Kα mutation HR+/HER2- Breast Cancer ~14k ~18k ~120k pt 1L 2L (Neo)adjuvant RLY-2

  11. Slide 11: RLY-2608 – Safety Profiles of Existing PI3Kα Pathway Compounds

    RLY-2608 – Safety Profiles of Existing PI3Kα Pathway Compounds 9% 6% 72% 60% 12% 10% 19% 38% 29% 2% 14% 16% 59% 62% Gr3+ Gr1-2 Diarrhea Rash Hyperglycemia Safety & Tolerability Sources: 1. Turner N Engl J Med 2023; 388:2058-2070; 2. Rugo 2021 Lancet Oncol 22:489; 3. SABCS 2021 #P5-17-05; * For PIK3C

  12. Slide 12: RLY-2608 – Efficacy Profiles of Existing PI3Kα Pathway Compounds

    RLY-2608 – Efficacy Profiles of Existing PI3Kα Pathway Compounds 7.3 97% 47% 42% 100% 0% 6% 70% 0% 18% RW mPFS ~4-6mo vs. 8mo ByLIEVE 5.5mo PFS in CDK4/6-experienced pt Sources: 1. Turner N Engl J Med 2023; 388:2058-2070; 2. Rugo 2021 Lancet Oncol 22:489; 3. SABCS 2021 #P5-17-05; * For PIK3CAmut HR+

  13. Slide 13: SABCS 2023 – Encouraging Validation of PI3Kα Targeting in 1L Breast Cancer

    SABCS 2023 – Encouraging Validation of PI3Kα Targeting in 1L Breast Cancer Source: SABCS 2023 GS03-13 Inavolisib + Palbociclib + Fulvestrant doubled PFS vs. Fulvestrant + Palbociclib Alone 15.0mo mPFS Vs. 7.3mo pbo HR: 0.43 However, INAVO120 Ph 3 Trial Included Only a Subset of 1L HR+/HER2- Breast C

  14. Slide 14: PI3Kα – Proprietary Insights Unlock Novel Approaches

    PI3Kα – Proprietary Insights Unlock Novel Approaches A differentiated understanding of the structure of PI3Kα and its relationship to function equips Relay Tx to design optimal mutant-selective inhibitors of PI3Kα Designed pan-mutant selective PI3Kα inhibitor (PI3KαPAN) Discovered novel allosteric p

  15. Slide 15: RLY-2608 – ReDiscover Trial Interim Part Results Dose Escalation

    RLY-2608 – ReDiscover Trial Interim Part 1 Results Dose Escalation Favorable PK Profile Across Dose Levels ~50% pAKT inhibition 400mg 200mg 100mg 800mg 600mg BID ~80% pAKT inhibition (predicted from mouse PK/PD models) ~50% pAKT inhibition No DLTs and MTD has yet to be defined Dose-dependent increas

  16. Slide 16: RLY-2608 – 600 mg BID Dose Selected for Expansion Cohort

    RLY-2608 – 600 mg BID Dose Selected for Expansion Cohort 17 Breast Cancer Patients Treated with RLY-2608 600 mg BID Dose + Fulvestrant Preliminary data as of 07/24/2023 Breast Cancer Patients 600 mg BID RLY-2608 + Fulvestrant (N=17) RLY 2608 + Fulvestrant 600mg BID: 86% (6/7) CBR in patients with at

  17. Slide 17: RLY-2608 – Limited Observed Impact on Glucose Homeostasis

    Note: one 1000mg BID combo pt not shown; pt had Gr2 glucose elevation per alpelisib label criteria; Data represent mean per cohort +/- standard deviation Source: Central lab analysis RLY-2608 – Limited Observed Impact on Glucose Homeostasis Supports Selectivity Grade 3 (250-500 mg/dL) Grade 2 (160-2

  18. Slide 18: RLY-2608 – Safety Profiles of Existing PI3Kα Pathway Compounds

    RLY-2608 – Safety Profiles of Existing PI3Kα Pathway Compounds Data below are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population and many other factors. Ph1b Arm D (N=60)3 Inavolisib + fulvestrant Ph1b

  19. Slide 19: RLY-2608 – ReDiscover Trial Design – Doublet

    RLY-2608 – ReDiscover Trial Design – Doublet Dose Escalation Dose Expansion RLY-2608 + Fulvestrant Doublet 400mg BID 200mg BID 100mg BID 800mg BID 600mg BID 1000mg BID Expansion cohort (opened July 2023) Add'l Expansion Cohort (4Q 2023) 600mg BID (N=20) 600mg BID (N=20) 400mg BID (N=20) Dose escalat

  20. Slide 20: RLY-2608 – ReDiscover Trial Design – CDK4/6 Triplet

    RLY-2608 – ReDiscover Trial Design – CDK4/6 Triplet Initial Ribociclib triplet safety data to be disclosed in 2H 2024 RLY-2608 + Fulvestrant Doublet 600mg BID (N=20) 400mg BID (N=20) 2L+ 1000mg BID 800mg BID 600mg BID 400mg BID 200mg BID 100mg BID RLY-2608 + Fulvestrant + Ribociclib Triplet RLY-2608

  21. Slide 21: RLY-2608 – ReDiscover Combination Trial Design

    RLY-2608 – ReDiscover Combination Trial Design Dose Escalation Dose Expansion RLY-2608 + Fulvestrant Doublet 2L+ RLY-2608 + Fulvestrant + Ribociclib Triplet 1L / 2L 600mg BID (N=20) 400mg BID (N=20) 1000mg BID 800mg BID 600mg BID 400mg BID 200mg BID 100mg BID 600mg BID (N=20) 600 mg expansion cohort

  22. Slide 22: RLY-2608 – ReDiscover Milestones

    RLY-2608 – ReDiscover Milestones Next RLY-2608 data update in 2H 2024 Study Arm Dose Escalation Dose Expansion RLY-2608 + Fulvestrant + Ribociclib Triplet Potential Line of Tx 1L / 2L Ribociclib Triplet cohort Initiated Q4 2023 Ribociclib triplet safety data in 2H 2024 RLY-2608 + Fulvestrant Doublet

  23. Slide 23: Relay Tx – Broad Precision Medicine Pipeline

    Relay Tx – Broad Precision Medicine Pipeline Target Program PI3Kα franchise RLY-2608 PI3KαPAN Monotherapy Endocrine Tx (ET) doublet CDK4/6i + ET triplet RLY-5836 (PI3KαPAN) Dose Escalation PI3KαH1047R FGFR2 Lirafugratinib (RLY-4008) Solid Tumor 2 programs Genetic Disease 2 programs CDK2 RLY-2139 ERα

  24. Slide 24: FGFR2 – Limitations of Current CCA and Non-CCA Treatment Options

    FGFR2 – Limitations of Current CCA and Non-CCA Treatment Options 1. Sources: Pemigatinib – prescribing information; futibatinib – prescribing Information; erdafitinib – prescribing information; (note: AEs are reflective of respective label indications); 2. Reflects reported ORRs in key randomized st

  25. Slide 25: Lirafugratinib (RLY-4008) – Embodies The Power of Our R&D Engine

    Lirafugratinib (RLY-4008) – Embodies The Power of Our R&D Engine Motion Based Drug Design… ...Created First Known Selective FGFR2 Strong Clinical Execution Drives Rapid Pathway to Potential Registration FGFR2 Relay Approach First Patient Dosed Sep 2020 Oct 2023 Patients Treated Within 3 Years1 ~450

  26. Slide 26: Lirafugratinib (RLY-4008) – Evolution of Data Maturity

    Lirafugratinib (RLY-4008) – Evolution of Data Maturity 2021 – Initial Clinical Activity Demonstrated1 2022 – Interim Efficacy in CCA Fusion2 2023 – Interim Tumor Agnostic Efficacy3 Non-CCA Fusions 35% Amps 24% Muts 13% Breast 40% Gastric 19% NSCLC 2of4 N = 49 (All solid tumors) N = 38 (fusion+, FGFR

  27. Slide 27: Relay Tx – Broad Precision Medicine Pipeline

    Relay Tx – Broad Precision Medicine Pipeline Target Program PI3Kα franchise RLY-2608 PI3KαPAN Monotherapy Endocrine Tx (ET) doublet CDK4/6i + ET triplet RLY-5836 (PI3KαPAN) Dose Escalation PI3KαH1047R FGFR2 Lirafugratinib (RLY-4008) Solid Tumor 2 programs Genetic Disease 2 programs CDK2 RLY-2139 ERα

  28. Slide 28: SHP2 – Genentech Global Collaboration for Migoprotafib (GDC-1971)

    SHP2 – Genentech Global Collaboration for Migoprotafib (GDC-1971) Collaboration provides meaningful economics to Relay Tx1 Migoprotafib + Atezolizumab (PD-L1 Ab) initiated August 2022 Migoprotafib + GDC-6036 (KRAS G12Ci) initiated July 2021 Unconfirmed ORR: 53% (30/57 patients) Confirmed ORR: 46% (2

  29. Slide 29: Relay Tx – Broad Precision Medicine Pipeline

    Relay Tx – Broad Precision Medicine Pipeline Target Program Annual US Patient # PI3Kα franchise RLY-2608 PI3KαPAN Monotherapy ~10-71K breast cancer ~76-243K all solid tumors Endocrine Tx (ET) doublet CDK4/6i + ET triplet RLY-5836 (PI3KαPAN) Dose Escalation PI3KαH1047R ~4-27K breast cancer ~15-50K al

  30. Slide 30: Relay Tx’s Execution Focus

    Relay Tx’s Execution Focus Continuing to achieve the goals we set JPM Conference 2021 JPM Conference 2023 JPM Conference 2022 JPM Conference 2020

  31. Slide 31: Capital, Team & Execution Focus to Deliver on Milestones

    Relay Tx – Capital, Team & Execution Focus to Deliver on Milestones 2024 Corporate Objectives Cash, cash equivalents and investments as of the end of 3Q 2023 ~$811M Expected to be sufficient to fund current operating plan into 2H 2026 Significant Capital to Achieve Goals RLY-2608 Doublet (PI3Kα) Add

  32. Slide 32: Slide 32

Relay Therapeutics — J.P. Morgan Healthcare Conference 2024 on 6ix